Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. EKSO
stocks logo

EKSO

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
5.03M
-1.27%
-0.350
-83.33%
4.55M
+34.81%
-0.430
-76.11%
4.30M
+109.04%
-0.240
-80.65%
Estimates Revision
The market is revising No Change the revenue expectations for Ekso Bionics Holdings, Inc. (EKSO) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 0.74%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Up
up Image
+0.74%
In Past 3 Month
Wall Street analysts forecast EKSO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EKSO is 6.00 USD with a low forecast of 6.00 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast EKSO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EKSO is 6.00 USD with a low forecast of 6.00 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 4.070
sliders
Low
6.00
Averages
6.00
High
6.00
Current: 4.070
sliders
Low
6.00
Averages
6.00
High
6.00
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$4 -> $6
2025-11-18
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$4 -> $6
2025-11-18
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Ekso Bionics to $6 from $4 and keeps a Buy rating on the shares. The company reported a solid Q3 report and announced it has initiated a strategic review of the current business, the analyst tells investors in a research note. The firm does not account for any transaction at this time. Ekso's sales recovery in Q3 implies that order delays from the prior quarter "appear to be idiosyncratic," but it remains to be seen if this trend can continue, contends H.C. Wainwright.
Lake Street
Buy
downgrade
$15
2025-07-29
Reason
Lake Street
Price Target
$15
2025-07-29
downgrade
Buy
Reason
Lake Street lowered the firm's price target on Ekso Bionics to $9.50 from $15 and keeps a Buy rating on the shares. Q2 revenue fell "well below" the firm's expectations, attributable to the company's Enterprise Health business. While the firm does not believe investors "should become overly concerned with the company's Q2 results," it recognizes improvements "may not be readily evident prior to the company requiring additional funds."
HC Wainwright & Co.
Swayampakula Ramakanth
Strong Buy
Reiterates
$9
2025-03-04
Reason
HC Wainwright & Co.
Swayampakula Ramakanth
Price Target
$9
2025-03-04
Reiterates
Strong Buy
Reason
Lake Street
Ben Haynor
Strong Buy
Maintains
$2 → $1
2025-03-04
Reason
Lake Street
Ben Haynor
Price Target
$2 → $1
2025-03-04
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Swayampakula Ramakanth
Strong Buy
Reiterates
$9
2025-01-14
Reason
HC Wainwright & Co.
Swayampakula Ramakanth
Price Target
$9
2025-01-14
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Ekso Bionics Holdings Inc (EKSO.O) is -3.63, compared to its 5-year average forward P/E of -3.12. For a more detailed relative valuation and DCF analysis to assess Ekso Bionics Holdings Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.12
Current PE
-3.63
Overvalued PE
-1.35
Undervalued PE
-4.89

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.54
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.86
Undervalued EV/EBITDA
-2.94

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
2.07
Current PS
0.00
Overvalued PS
4.27
Undervalued PS
-0.12
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

EKSO News & Events

Events Timeline

(ET)
2025-12-04
07:50:00
Ekso Bionics Enters Exclusive Sales Agreement with MediTouch
select
2025-10-29 (ET)
2025-10-29
08:05:26
Ekso Bionics sets price for 769,490 shares at $4.81 in a registered direct offering
select
2025-10-28 (ET)
2025-10-28
16:42:33
Ekso Bionics Announces Q3 Earnings Per Share of 54 Cents, Below Consensus Estimate of 96 Cents
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
8.0
11-27TipRanks
China Warns of Potential Risks in Humanoid Robot Investment Surge

  • China's Warning on Humanoid Robotics: The National Development and Reform Commission of China has issued a warning about the rapid growth of the humanoid robotics sector, indicating potential market overheating and a risk of a bubble due to the increasing number of similar companies.

  • Market Regulation Plans: The agency plans to implement stricter regulations for market entry and exit, aiming to foster fair competition and support the development of key technologies in the humanoid robotics industry.

  • Leading Companies in the Sector: Notable companies in the humanoid robotics market include UBTECH Robotics and Unitree Robotics in China, and Figure AI and Boston Dynamics in the U.S., with significant investments and projected growth in sales.

  • Global Robotics Market Growth: The global robotics market is experiencing strong growth, with total industry sales expected to reach $50 billion in 2025, driven primarily by mobile and industrial robots, while humanoid robots are gaining a larger share of the market.

[object Object]
Preview
4.0
11-22NASDAQ.COM
Ekso Bionics (EKSO) Receives Upgrade to Buy: Reasons Explained

  • Zacks Rank Upgrade: Ekso Bionics has been upgraded to a Zacks Rank #2 (Buy) due to a positive trend in earnings estimates, indicating potential for stock price increase.

  • Earnings Estimate Revisions: The Zacks Consensus Estimate for Ekso Bionics has risen by 21.4% over the past three months, reflecting improved earnings outlook and business fundamentals.

  • Investment Strategy: The Zacks rating system, which maintains a balanced distribution of buy and sell ratings, suggests that stocks in the top 20% are likely to outperform the market based on earnings estimate revisions.

  • Future Earnings Projection: Analysts project Ekso Bionics will earn -$0.92 per share for the fiscal year ending December 2025, with no year-over-year change expected.

[object Object]
Preview
9.5
11-20NASDAQ.COM
Earnings Growth Boosts PACS and Nutex; Zynex and Genenta Also Rise in After-Hours Trading

  • PACS Group Performance: PACS Group Inc. saw a significant after-hours surge of 45.48% to $24.48, following a strong quarterly report showing a net income increase to $52.4 million and revenue growth to $1.345 billion.

  • Zynex, Inc. Update: Zynex, Inc. experienced a 4.49% rise after hours to $0.58, despite reporting a net loss of $42.9 million for the quarter, down from a profit in the same period last year.

  • Genenta Science Recovery: Genenta Science S.p.A. rose 7.34% after hours to $1.90, recovering from a previous decline, with no new updates but a recent securities purchase agreement raising approximately $15 million.

  • Nutex Health Growth: Nutex Health Inc. advanced 9.64% after hours to $123.00, following a strong quarterly performance with a net income of $55.4 million and a revenue increase of 239.9% to $267.8 million.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Ekso Bionics Holdings Inc (EKSO) stock price today?

The current price of EKSO is 4.07 USD — it has decreased -7.92 % in the last trading day.

arrow icon

What is Ekso Bionics Holdings Inc (EKSO)'s business?

Ekso Bionics Holdings, Inc. designs, develops, and markets exoskeleton products. Its exoskeleton technology serves people with physical disabilities or impairments in both physical rehabilitation and mobility. It operates as one segment with two markets: Enterprise Health and Personal Health. Its products include EksoNR, which is a wearable robotic exoskeleton designed for a rehabilitation setting; Ekso Indego Therapy is a modular, adjustable, lightweight, lower limb-powered exoskeleton; Ekso Indego Personal is a lower limb orthosis; Ekso Nomad is a power Knee Ankle Foot Orthosis, and Ekso EVO is a wearable upper body exoskeleton. It enables individuals with neurological conditions affecting gait, including acquired brain injury (ABI) and spinal cord injury (SCI), to rehabilitate, stand and walk again. Additionally, the devices assist people with a variety of upper extremity disabilities and enable industrial employees to perform challenging repetitive tasks for extended periods.

arrow icon

What is the price predicton of EKSO Stock?

Wall Street analysts forecast EKSO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EKSO is 6.00 USD with a low forecast of 6.00 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Ekso Bionics Holdings Inc (EKSO)'s revenue for the last quarter?

Ekso Bionics Holdings Inc revenue for the last quarter amounts to 4.23M USD, increased 2.37 % YoY.

arrow icon

What is Ekso Bionics Holdings Inc (EKSO)'s earnings per share (EPS) for the last quarter?

Ekso Bionics Holdings Inc. EPS for the last quarter amounts to -0.54 USD, decreased -64.71 % YoY.

arrow icon

What changes have occurred in the market's expectations for Ekso Bionics Holdings Inc (EKSO)'s fundamentals?

The market is revising No Change the revenue expectations for Ekso Bionics Holdings, Inc. (EKSO) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 0.74%.
arrow icon

How many employees does Ekso Bionics Holdings Inc (EKSO). have?

Ekso Bionics Holdings Inc (EKSO) has 61 emplpoyees as of December 05 2025.

arrow icon

What is Ekso Bionics Holdings Inc (EKSO) market cap?

Today EKSO has the market capitalization of 10.68M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free